Hopp til innhold
NHI.no
Annonse

Hjertesvikt, kronisk: Når bør du kontakte lege?

Innhold i artikkelen

Ved akutte alvorlige symptomer, kontakt legevakt (telefon 116117) eller ring 113.
Dette gjelder dersom du har:

  • Alvorlig tung pust, pustevansker eller kvelningsfornemmelse
  • Plutselig sterke brystsmerter
  • Besvimelse eller alvorlig svimmelhet
Annonse

Ta kontakt med fastlegen din hvis du opplever symptomer som kan tyde på hjertesvikt:

  • Vedvarende tung pust, spesielt i hvile eller når du legger deg ned
  • Hovne ankler, bein eller mage (væskeansamling)
  • Uforklarlig slapphet, økt trettbarhet eller nedsatt yteevne
  • Uvanlig hjertebank, svimmelhet eller besvimelsesanfall
  • Redusert matlyst eller uforklarlig vektøkning

Merk at disse plagene kan ha mange årsaker, men det er viktig at en lege vurderer deg, spesielt hvis du har risikofaktorer som høyt blodtrykk, gjennomgått hjerteinfarkt, diabetes eller annen hjertesykdom.

Dersom du allerede er under behandling for hjertesvikt

Kontakt lege dersom du opplever:

  • Rask vektøkning (mer enn 2 kg på 1–3 dager)
  • Forverring av tung pust, spesielt i hvile eller om natten
  • Hovne bein eller mage som blir tydelig verre
  • Plutselig økt tretthet, svimmelhet, hjertebank eller besvimelsesanfall
  • Uvanlig tørrhoste, surkling i brystet eller nattlig hoste
  • Redusert urinmengde, eller tegn til uttørking (spesielt ved feber, oppkast eller diaré)
  • Sterk hjertebank eller uregelmessig puls

Vær også oppmerksom dersom du får bivirkninger av medisiner, eller er usikker på egen behandling. God oppfølging og tidlig kontakt med lege kan bidra til å forhindre forverring av hjertesvikt.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Hjertesvikt, kronisk . Referanselisten for dette dokumentet vises nedenfor

  1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021. doi:10.1093/eurheartj/ehab368 DOI
  2. Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown, 1994.
  3. Kringeland, E., Slungård, G. F., Forster, R. B., Akerkar, R., & Eriksen, S. H. W. (2023). Hjerte- og karregisteret – Rapport for 2022. Folkehelseinstituttet. www.fhi.no
  4. Folkehelseinstituttet. Forekomst av hjerte- og karsykdommer i 2020. FHI 2021. www.fhi.no
  5. Gullestad L og Broch K. Kronisk hjertesvikt anno 2022. Hjerteforum 2022; 35: 14-26. www.legeforeningen.no
  6. Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017 Dec;19(12):1574-1585. Epub 2017 Apr 6. PMID: 28386917.
  7. Aarønæs M, Atar D, Bonarjee V, et al. Kronisk hjertesvikt - etiologi og diagnostikk. Tidsskr Nor Lægeforen 2007; 127: 171-3. PubMed
  8. Rush CJ, Berry C, Oldroyd KG, et al. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 2021. pmid:34160566 PubMed
  9. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-53. PubMed
  10. Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction The STOP-CA Randomized Clinical Trial. JAMA 2023; 330: 528-536. pmid:37552303 PubMed
  11. Utredning, behandling og oppfølging av hjertesvikt i allmennpraksis. Veileder utarbeidet av arbeidsgruppen for hjertesvikt i Norsk cardiologisk selskap. Versjon august 2024. Lest 14.10.2024 www.legeforeningen.no
  12. Fuery MA, Leifer ES, Samsky MD, et al. Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2023. pmid:38127049 PubMed
  13. Dosh SA. Diagnosis of heart failure in adults. Am Fam Physician 2004; 70: 2145-52. PubMed
  14. Real J, Cowles E, Wierzbicki AS, et al. Chronic heart failure in adults: summary of updated NICE guidance. BMJ 2018; 362: k3646. PMID: 30249604 PubMed
  15. Modin D, Jørgensen ME, Gislason G, et al. Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. Circulation 2018. pmid:30586760 PubMed
  16. Folkehelseinstituttet. Pneumokokkvaksine - veileder for helsepersonell. Sist oppdatert 27.09.2022. Siden lest 18.10.2022 www.fhi.no
  17. Zhao Q, Chen C, Zhang J, et al. Effects of self-management interventions on heart failure: Systematic review and meta-analysis of randomized controlled trials. Int J Nurs Stud. 2020 Jun 16;110:103689. PMID: 32679402 PubMed
  18. Colin-Ramirez E, Sepehrvand N, Rathwell S, Ross H, Escobedo J, Macdonald P, Troughton R, Saldarriaga C, Lanas F, Doughty R, McAlister FA, Ezekowitz JA. Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Circ Heart Fail. 2023 Jan;16(1):e009879. PMID: 36373551 PubMed
  19. Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet 2022; 399: 1391-1400. pmid:35381194 PubMed
  20. Mandras SA, Uber PA, Mehra MR. Sexual activity and chronic heart failure. Mayo Clin Proc 2007; 82: 1203-10. PubMed
  21. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease. JAMA 2012; 308: 1024-33. Journal of the American Medical Association
  22. Suebsaicharoen T, Chunekamrai P, Yingchoncharoen T, et al. Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials. OpenHeart 2023; 10: e002364. pmid:37940331 PubMed
  23. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021. pmid:34449189 PubMed
  24. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022. doi:10.1016/S0140-6736(22)01429-5 DOI
  25. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022. doi:10.1056/NEJMoa2206286 DOI
  26. Mc Causland FR, Claggett BL, Vaduganathan M, et al. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol 2022. pmid:36326604 PubMed
  27. Butler J, Usman MS, Filippatos G, et al. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial. JAMA Cardiol 2023. pmid:37223933 PubMed
  28. Butler J, Filippatos G, Siddiqi TJ, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved Trial. Circulation 2021. pmid:34779658 PubMed
  29. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2022. PMID: 36526515 PubMed
  30. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2023. doi:10.1093/eurheartj/ehad195 DOI
  31. Kosiborod MN, Verma S, Borlaug BA, et al. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation 2023. PMID: 37952180 PubMed
  32. Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024; 403: 1635-1648. pmid:38599221 PubMed
  33. Petrie MC, Verma S, Docherty KF, et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA 2020; 323: 1353-68. pmid:32219386 PubMed
  34. Writing Committee; Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77: 772-810. pmid:33446410 PubMed
  35. Svanström H, Mkoma GF, Hviid A, Pasternak B. SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study. BMJ 2024; 387: e800925. pmid:39505389 PubMed
  36. Zou X, Shi Q, Vandvik PO, et al. Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure : A Systematic Review and Meta-analysis. Ann Intern Med. 2022. PMID: 35404670 PubMed
  37. Berg DD, Jhund PS, Docherty KF, et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol 2021; 6: 499-507. pmid:33595593 PubMed
  38. Docherty KF, Jhund PS, Claggett B, et al. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol 2021. doi:10.1001/jamacardio.2021.2632 DOI
  39. Biegus J, Voors AA, Collins SP, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2022. PMID: 36254693 PubMed
  40. Ferreira JP, Zannad F, Butler J, et al. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J 2022. pmid:35687107 PubMed
  41. Joshi SJ, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart 2021. pmid:33637556 PubMed
  42. Causland FRM, Claggett B, Vaduganathan M, et al. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol 2023. pmid:37952176 PubMed
  43. Savage HO, Dimarco AD, Li B, et al. Sequencing of medical therapy in heart failure with a reduced ejection fraction. Heart 2022. pmid:36368882 PubMed
  44. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure. Lancet 1999; 353: 2001-07.
  45. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370:1383-92. doi: 10.1056/NEJMoa1313731 DOI
  46. Filippatos G, Anker SD, Agarval R, et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation 2021. pmid:34775784 PubMed
  47. Oraii A, Healey JS, Kowalik K, et al. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials. Eur Heart J 2024. pmid:38195054 PubMed
  48. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Card Fail 2022; 28: 810-830. pmid:35378259 PubMed
  49. Nielsen EE, Feinberg JB, Bu F-L, et al. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Open Heart 2020; 7: e001294. pmid:33257469 PubMed
  50. Foa A, Vaduganathan M, Claggett BL, et al. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol 2024; 83: 1731-1739. pmid:38537919 PubMed
  51. McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan, versus valsartan, in women compared to men with heart failure and preserved ejection fraction: Insights from PARAGON-HF. Circulation 2019. PMID: 31736337 PubMed
  52. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85. PMID: 20801500 PubMed
  53. Armstrong PW, Pieske B, Anstrom KJ, et. al, VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883–1893. PMID: 32222134 PubMed
  54. Liew AY, Eikelboom JW, Connolly SJ, et al. Efficacy and safety of warfarin vs. antiplatelet therapy in patients with systolic heart failure and sinus rhythm: a systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2014 ;9(2):199-206. doi: 10.1111/ijs.12036 DOI
  55. Lip GYH, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD003336. DOI: 10.1002/14651858.CD003336.pub3. Accessed 13 April 2021 The Cochrane Library
  56. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-5. Circulation
  57. Pasqualotto E, Ternes CMP, Chavez MP, et al. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction patients: A meta-analysis. Heart Rhythm 2024. pmid:38705438 PubMed
  58. Graham FJ, Guha K, Cleland JG, et al. Treating iron deficiency in patients with heart failure: what, why, when, how, where and who. Heart 2024. pmid:39160066 PubMed
  59. Ponikowski P, Kirwan B-A, Anker SD, et al on behalf of the AFFIRM-AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial. Lancet 2020. PMID: 33197395 PubMed
  60. Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022; 400: 2199-2209. pmid:36347265 PubMed
  61. Mentz RJ, Garg J, Rockhold FW, et al. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med 2023. doi:10.1056/NEJMoa2304968 DOI
  62. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019. pmid:31535829 PubMed
  63. Zhou X, Xu W, Xu Y, et al. Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure. Am J Med. 2019. PMID: 30853478 PubMed
  64. Schou M, Gustafsson F, Videbaek L, et al. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J. 2012 Aug 8. pmid:PMID: 22875412 PubMed
  65. Long L, Mordi IR, Bridges C, et al. Exercise‐based cardiac rehabilitation for adults with heart failure. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No.: CD003331. DOI: 10.1002/14651858.CD003331.pub5. The Cochrane Library
  66. Pandey A, Parashar A, Kumbhani DJ, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8(1):33-40. doi: 10.1161/CIRCHEARTFAILURE.114.001615. DOI
  67. Mueller S, Winzer EB, Duvinage A, et al. Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction A Randomized Clinical Trial. JAMA 2021; 325: 542-51. pmid:33560320 PubMed
  68. Wang C, Xing J, Zhao B, Wang Y, Zhang L, Wang Y, Zheng M, Liu G. The Effects of High-Intensity Interval Training on Exercise Capacity and Prognosis in Heart Failure and Coronary Artery Disease: A Systematic Review and Meta-Analysis. Cardiovasc Ther. 2022 Jun 9;2022:4273809. MCID: PMC9203221
  69. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019 Apr 16;139(16). PMID: 30852913. PubMed
  70. Ostrominski JW, Greene SJ, Patel RB, et al. Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure. JAMA Cardiol 2024. pmid:38809567 PubMed
  71. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80. PMID: 11401110 PubMed
  72. Hsu JJ, Ziaeian B, Fonarow GC. Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. JACC Heart Fail. 2017 Nov;5(11):763-771.Eub 2017 Oct 11. PMID: 29032140 PubMed
  73. Tsimploulis A, Lam PH, Arundel C, et al. Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction. JAMA Cardiol 2018. pmid:29450487 PubMed
  74. Taylor CJ, Lay-Flurrie SL, Ordóñez-Mena JM, et al. Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018. Heart 2021. pmid:34183432 PubMed
  75. Taylor CJ, Ordonez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ. 2019 Feb 13;364:l223. PMID: 30760447 PubMed
  76. Berge K, Brynildsen J, Røysland R, et al. Prognostic value of cardiac biomarkers and National Early Warning Score 2 in acute dyspnoea. Open Heart 2022. pmid:35387863 PubMed
  77. Norsk kvalitetsforbedring av laboratorieundersøkelser (Noklus). Anbefalte analyser ved ulike kliniske problemstillinger. Siden besøkt 21.09.2020. www.noklus.no
Annonse
Annonse